Market uncertainty makes it more critical than ever to understand how your consumer base is thinking and feeling about the GLP-1 landscape
Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A (2020) Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
Probiotics dont do that
additional glucose lowering treatment should be considered, as needed
The microdosing tirzepatide chart , microdose tirzepatide schedule , and microdosing GLP-1 for autoimmune conditions explore this approach
Around the same time, I think you remember that all of pharma was interested in obesity in the early 90s, everyone wanted to do diabetes as well as obesity, but they were separate teams and they all wanted to do small molecules, but it just happens to be so that the best idea we could find at that time was actually GLP-1, because we actually had clinical data relatively early that GLP-1 was a really good candidate as a treatment for diabetes because of the glucose sensitivity of the actions
)
